主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
PLX
#3115
Protalix BioTherapeutics, Inc. Common Stock
2.830
0
USD
+1.07%
版块:
医疗保健
基础:
USD
利润货币:
USD
日范围
年范围
日变化
+1.07%
每月变动
-3.08%
6个月变化
-3.08%
年变化
-3.08%
前一天收盘价
2.800
0
Open
2.820
0
Bid
2.830
0
Ask
2.833
0
Low
2.789
0
High
2.845
0
交易量
288
市场
股票
医疗保健
PLX
Open full chart
Financials
Overview
声明
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
45.38 M
46.32 M
57.35 M
73.05 M
78.03 M
—
Valuation ratios
Enterprise value
146.47 M
-463.88 K
61.46 M
109.32 M
126.94 M
576.27 M
Price to earnings ratio
—
-1.34
-4.42
20.22
47
142.39
Price to sales ratio
—
0.96
1.39
2.29
2.85
10.78
Price to cash flow ratio
—
3.57
2.66
113.82
17.57
54.4
Price to book ratio
—
6.08
6.24
4.47
3.53
6.41
Enterprise value to EBITDA ratio
19.58
-0.02
2.25
2.7
-36.71
66.6
Profitability ratios
Return on assets %
0.1
0.37
0.27
0.1
0.04
0.01
Return on equity %
0.24
4.57
1.4
0.25
0.07
0.02
Return on invested capital %
—
—
251.84
146.84
30.81
10.67
Gross margin %
82.71
57.37
58.87
64.91
54.46
213.66
Operating margin %
4.31
53.36
27.32
15.97
7.34
24.99
EBITDA margin %
11.89
63.31
57.44
61.9
-6.48
1.05
Net margin %
10.37
71.92
31.33
12.69
5.49
18.09
Liquidity ratios
Quick ratio
0.49
1.32
0.87
1.12
1.52
7.1
Current ratio
0.64
1.86
1.38
1.54
2.34
10.58
Inventory turnover
0.03
0.03
0
0.04
0
—
Asset turnover
1.11
0.54
0.74
0.93
0.68
0.83
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
0.86
0.38
0.51
0.24
0
—
Long term debt to total equity ratio
2.16
4.62
2.65
0.6
0
—
Per share metrics
Operating cash flow per share
—
0.23
0.52
0.02
0.11
0.23
EBIT per share
—
0.46
0.54
0.47
-0.06
0.04
EBITDA per share
—
0.55
0.56
0.49
-0.04
0.06
Total debt per share
—
—
—
—
—
—
Cash per share
—
0.88
0.35
0.29
0.24
0.9
Net current asset value per share
—
1.4
0.93
0.85
0.74
3.22
Tangible book value per share
—
0.14
0.22
0.41
0.53
2.44
Working capital per share
—
0.65
0.26
0.3
0.43
2
Book value per share
—
0.14
0.22
0.41
0.53
2.44
Protalix BioTherapeutics Inc (DE)
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
新闻
Brazil judge overrules decisions suspending changes to meal voucher system
A March Decision That Could Change Protalix’s Outlook (NYSE:PLX)
Pluxee, Edenred shares jump after upbeat results and outlook
Pluxee 2026财年第一季度报告:在巴西挑战中实现9%收入增长
Pluxee posts 9% growth in Q1; confirms 2026 outlook despite Brazil headwinds
Protalix公司概述2026年战略,聚焦难治性痛风疗法
Tuesday’s Insider Activity: Key Execs Make Notable Trades
Protalix BioTherapeutics首席执行官Bashan Dror购入价值10.1万美元股票
BioMarin: Amicus Buyout Sparks My Enthusiasm (NASDAQ:BMRN)
Protalix与Secarna合作开发罕见肾脏疾病治疗方案
Protalix and Secarna partner to develop rare kidney disease treatments
Pluxee因巴西监管变化修订2026财年展望